POLE encodes the catalytic subunit of DNA polymerase epsilon, the primary replicative polymerase responsible for synthesizing leading strands during chr12 DNA replication 1. Beyond replication, POLE possesses 3'-5' exonuclease proofreading activity that corrects replication errors and participates in DNA repair synthesis, including nucleotide-excision repair following UV irradiation 2. Pathogenic mutations in POLE's exonuclease domain cause loss of proofreading function, leading to accumulation of mutations and ultra-high tumor mutational burden (>100 mut/Mb) 34. POLE mutations define a distinct molecular subtype of endometrial and colorectal cancers associated with highly favorable prognosis; endometrial cancers with POLE exonuclease domain mutations show 5-year recurrence-free survival rates of 89-96%, superior to other molecular subtypes 56. Germline POLE variants predispose to adenomatous polyps, colorectal cancer, endometrial tumors, and other malignancies, with polymerase proofreading-associated syndrome constituting 0.1-0.4% of hereditary cancer cases 7. Notably, POLE/POLD1-mutated metastatic colorectal cancer demonstrates superior immunotherapy response (89% overall response rate) compared to mismatch repair-deficient tumors, suggesting POLE status serves as a predictive biomarker for immune checkpoint inhibitor efficacy 8.